Compare Regeneron Pharmaceuticals Inc (REGN) vs Schlumberger NV (SLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Schlumberger NV — how do they compare? Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B), while Schlumberger NV trades at $48.97 (market cap $71.18B). The key difference: Regeneron Pharmaceuticals Inc and Schlumberger NV are close in size by market cap, and Schlumberger NV pays the higher dividend (2.46%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Schlumberger NV for 99 Days on average.
| REGN | SLB | |
|---|---|---|
Market Cap | $76.40B | $71.18B |
Volume | 626,381 | 14,872,321 |
Sector | Health | Energy |
52-Week High | $852.03 | $60.10 |
52-Week Low | $557.73 | $31.72 |
Typical Hold Time | 107 Days | 99 Days |
Enterprise Value | $71.12B | $79.91B |
Dividend Yield | 0.51% | 2.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
SLB trades at $47.96, down 4.08% in the last session, with technical indicators showing bearish momentum. The company maintains strong fundamentals with consistent earnings beats and a robust $35.71B revenue base, though 2025 net income declined to $3.37B. Recent contract wins in Saudi Arabia, Oman, and Mozambique provide multi-year revenue visibility, supporting analyst optimism with an 84.85% buy rating and $64.58 consensus price target.
SLB presents a compelling value opportunity with significant upside to analyst targets, driven by expanding international contracts and solid cash flow generation. Key risks include oil price volatility and execution challenges in new projects. The stock's current technical weakness may offer an attractive entry point for long-term investors seeking energy sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Schlumberger NV
Schlumberger is the largest oilfield service firm in the world, with expertise in myriad disciplines, including reservoir performance, well construction, production enhancement, and more recently, digital solutions. It maintains a reputation as one of the industry's leading innovators, which has earned it dominant share in numerous end markets.
Read more on SLB →
